Citable company snapshot
Boston Scientific's latest SEC-sourced 2026-03-31 period shows $5.20B in revenue and $1.34B in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $5.20B | $5.29B | -1.6% |
| xbrl:GrossProfit | Mar 31, 2026 | $3.61B | $3.68B | -1.7% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $1.10B | $825.00M | +33.5% |
| xbrl:NetIncomeLossAvailableToCommonStockholdersBasic | Mar 31, 2026 | $1.34B | $672.00M | +99.6% |
| xbrl:NetCashProvidedByUsedInOperatingActivities | Mar 31, 2026 | $348.00M | $1.36B | -74.5% |
| Free Cash Flow (computed) | Mar 31, 2026 | $171.00M | $1.01B | -83.1% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed May 1, 2026; accession 0000885725-26-000033.
Continue research
Follow same-sector companies and source explainers connected to the overview view.
A factual guide to market capitalization, shares outstanding, public float, and why share-count definitions matter.
A factual guide to dividends, share repurchases, and how companies can return capital to shareholders.
A factual guide to book value, tangible book value, and balance-sheet net worth measures.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.